The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). Oxaliplatin shows synergy with fluorouracil (FU), with little toxicity overlap. The XELOX regimen (capecitabine plus oxaliplatin), established in a previous dose-finding study, should improve on infused oxaliplatin with FU and leucovorin (FOLFOX) regimens. The present studies further characterize efficacy and safety of the XELOX regimen. Patients and Methods: The antitumor activity of XELOX was investigated in a colon cancer xenograft model. Patients with MCRC received first-line XELOX in 3-week treatment cycles: intravenous oxaliplatin 130 mg/m 2 (day 1) followed by oral capecitabine 1,000 mg/m 2 twice daily (day 1, evening, to day 15, morning). Results: A preclinical study confirmed that capecitabine has supra-additive activity with oxaliplatin. In the clinical study, 53 of 96 patients (55%) achieved an objective response, and 30 (31%) experienced disease stabilization for ≥ 3 months following treatment. After 24 months' minimum follow-up, median time to disease progression (TTP) and median overall survival were 7.7 and 19.5 months, respectively. XELOX safety was predictable and similar to the FOLFOX4 regimen, except that myelosuppression was uncommon with XELOX (grade 3 or 4 neutropenia, 7%). Most adverse events were mild to moderate, the most common being acute sensory neuropathy (85%). Sixty-day, all-cause mortality was 2%. Conclusion: XELOX is a highly effective first-line treatment for MCRC. Response rates, TTP, and overall survival are similar to those observed with FU/leucovorin/oxaliplatin combinations. XELOX provides a more convenient regimen, likely to be preferred by both patients and healthcare providers. Capecitabine has the potential to replace FU/LV in combination with oxaliplatin for MCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Self-citationHoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Self-citationOne-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003
de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf089 · Cited by 425
Self-citationCutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
Self-citationScheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E. L., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg500 · Cited by 276
Self-citationAndré, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E., Colbert, N., Boaziz, C., Piedbois, P., Tubiana-Mathieu, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.065 · Cited by 262
Scheithauer, W., Kornek, G. V., Raderer, M., Schüll, B., Schmid, K., Kovats, E., Schneeweiss, B., Lang, F., Lenauer, A., & Depisch, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.016 · Cited by 174
Borner, M. M., Dietrich, D., Stupp, R., Morant, R., Honegger, H., Wernli, M., Herrmann, R., Pestalozzi, B. C., Saletti, P., Hanselmann, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.087 · Cited by 169
Grothey, A. (2002) · Medical Entomology and Zoology · Cited by 167
Köhne, C.-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.122 · Cited by 160
Self-citationDíaz‐Rubio, E., Evans, T. R. J., Tabernero, J. M., Cassidy, J., Sastre, J., Eatock, M. M., Bisset, D., Regueiro, P., & Baselga, J. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf065 · Cited by 119
Self-citationTreatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A Phase II trial
Shields, A. F., Zalupski, M. M., Marshall, J. L., & Meropol, N. J. (2004) · Cancer · doi:10.1002/cncr.11925 · Cited by 66
Grothey, A. F., Büchele, T., Kroening, H., Ridwelski, K., Reichardt, P., Kretzschmar, A., Clemens, M. R., & Schmoll, H. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)81446-5 · Cited by 60
Cited by
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Self-citationColon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Metadata
- Authors
- Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., Schöffski, P., Sobrero, A., Van Cutsem, E., & Díaz-Rubio, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-01
- Volume
- 22
- Issue
- 11
- Pages
- 2084-2091
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113919377
- Cited by
- 525
- References
- 21
- FWCI
- 26.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.